PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk Visa övriga samt affilieringar
2022 (Engelska) Ingår i: Scientific Reports, E-ISSN 2045-2322, Vol. 12, nr 1, artikel-id 13264Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
PILRA (rs1859788 A > G) has been suggested to be a protective variant for Alzheimer’s disease (AD) and is an entry co-receptor for herpes simplex virus-1. We conducted a nested case–control study of 360 1:1-matched AD subjects. Interactions between the PILRA -A allele, APOE risk variants (ε3/ε4 or ε4/ε4) and GM 17 for AD risk were modelled. The associations were cross-validated using two independent whole-genome sequencing datasets. We found negative interactions between PILRA -A and GM 17 (OR 0.72, 95% CI 0.52–1.00) and between PILRA -A and APOE risk variants (OR 0.56, 95% CI 0.32–0.98) in the discovery dataset. In the replication cohort, a joint effect of PILRA and PILRA × GM 17/17 was observed for the risk of developing AD (p.02). Here, we report a negative effect modification by PILRA on APOE and GM 17 high-risk variants for future AD risk in two independent datasets. This highlights the complex genetics of AD.
Ort, förlag, år, upplaga, sidor Nature Publishing Group, 2022. Vol. 12, nr 1, artikel-id 13264
Nationell ämneskategori
Medicinsk genetik och genomik Folkhälsovetenskap, global hälsa och socialmedicin Mikrobiologi
Identifikatorer URN: urn:nbn:se:umu:diva-198480 DOI: 10.1038/s41598-022-17058-6 ISI: 000836651200031 PubMedID: 35918447 Scopus ID: 2-s2.0-85135234828 OAI: oai:DiVA.org:umu-198480 DiVA, id: diva2:1687082
Forskningsfinansiär EU, FP7, Sjunde ramprogrammet Region Västerbotten Kempestiftelserna Sveriges läkarförbund Demensförbundet Alzheimerfonden Hjärnfonden 2022-08-122022-08-122025-02-20 Bibliografiskt granskad